Skip to main content
Erschienen in: Medical Oncology 9/2014

01.09.2014 | Original Paper

Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival

verfasst von: Wenfeng Li, Zhengyang Xu, Junfeng Hong, Yunsheng Xu

Erschienen in: Medical Oncology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Enhanced glycolysis is a common trait of many types of human cancers. This study was to detect the expression pattern of three regulatory enzymes during glycolysis in esophageal squamous cell carcinoma (ESCC) and to investigate their correlation with patients’ outcome based on banked pathology material. A total of 141 surgically resected specimens of primary ESCC patients without prior treatments were retrospectively recruited from the First Affiliated Hospital of Wenzhou Medical College Hospital from 2007 to 2009. Expression of HK1, PFKB, and PKM2 in ESCC specimens was analyzed by immunohistochemical staining and Western blotting analysis. HK1-shRNA was used to knock down HK1 expression in ESCC cells, and the functional significance was assessed by CCK8 assay. It was found that the expression of two glycolytic enzymes, HK1 and PKM2, was associated with disease progression, invasion, and poor survival of patients with ESCC. Silence of HK1-inhibited cell proliferation in vitro and suppressed phospho-S6 kinase expression. Our findings suggest that activation of key enzymes in glycolysis might serve as potential therapeutic targets and/or prognostic factors for patients with ESCC.
Literatur
1.
Zurück zum Zitat Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.PubMedCrossRef Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.PubMedCrossRef
2.
Zurück zum Zitat Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, Hochwald SN. Esophageal cancer—the five year survivors. J Surg Oncol. 2011;103(2):179–83.PubMedCrossRef Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB, Hochwald SN. Esophageal cancer—the five year survivors. J Surg Oncol. 2011;103(2):179–83.PubMedCrossRef
3.
Zurück zum Zitat Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg. 2010;8(6):417–22.PubMedCrossRef Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G. Esophageal cancer: an update. Int J Surg. 2010;8(6):417–22.PubMedCrossRef
4.
Zurück zum Zitat Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2014;342(2):193–9.PubMedCrossRef Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2014;342(2):193–9.PubMedCrossRef
5.
Zurück zum Zitat Yokobori T, Kuwano H. Molecular biological review of esophageal cancer. Kyobu geka Japanese J Thorac Surg. 2013;66(1):73–84. Yokobori T, Kuwano H. Molecular biological review of esophageal cancer. Kyobu geka Japanese J Thorac Surg. 2013;66(1):73–84.
6.
Zurück zum Zitat Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45(8):625–9.PubMedCrossRef Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013;45(8):625–9.PubMedCrossRef
7.
Zurück zum Zitat Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111–6.PubMed Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111–6.PubMed
9.
Zurück zum Zitat Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PLoS Genet. 2008;4(12):e1000312.PubMedCrossRefPubMedCentral Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study. PLoS Genet. 2008;4(12):e1000312.PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chevre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, et al. Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes. 2009;58(11):2687–97.PubMedCrossRefPubMedCentral Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chevre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, et al. Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits. Diabetes. 2009;58(11):2687–97.PubMedCrossRefPubMedCentral
11.
Zurück zum Zitat Pinney SE, Ganapathy K, Bradfield J, Stokes D, Sasson A, Mackiewicz K, Boodhansingh K, Hughes N, Becker S, Givler S, et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr. 2013;80(1):18–27.PubMed Pinney SE, Ganapathy K, Bradfield J, Stokes D, Sasson A, Mackiewicz K, Boodhansingh K, Hughes N, Becker S, Givler S, et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr. 2013;80(1):18–27.PubMed
12.
Zurück zum Zitat Jiang L, Ren J, Xiao X, Tang YY, Weng HQ, Yang Q, Wu MJ, Tang W. Proteomic analysis of bladder cancer by iTRAQ after bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013;394(10):1333–42.PubMedCrossRef Jiang L, Ren J, Xiao X, Tang YY, Weng HQ, Yang Q, Wu MJ, Tang W. Proteomic analysis of bladder cancer by iTRAQ after bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013;394(10):1333–42.PubMedCrossRef
13.
Zurück zum Zitat Filipp FV. Cancer metabolism meets systems biology: pyruvate kinase isoform PKM2 is a metabolic master regulator. J Carcinogenesis. 2013;12:14.CrossRef Filipp FV. Cancer metabolism meets systems biology: pyruvate kinase isoform PKM2 is a metabolic master regulator. J Carcinogenesis. 2013;12:14.CrossRef
15.
Zurück zum Zitat Zhang X, He C, He C, Chen B, Liu Y, Kong M, Wang C, Lin L, Dong Y, Sheng H. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013;209(8):510–5.PubMedCrossRef Zhang X, He C, He C, Chen B, Liu Y, Kong M, Wang C, Lin L, Dong Y, Sheng H. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013;209(8):510–5.PubMedCrossRef
16.
Zurück zum Zitat Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41(4):917–22.PubMedCrossRef Nemazanyy I, Espeillac C, Pende M, Panasyuk G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 2013;41(4):917–22.PubMedCrossRef
17.
Zurück zum Zitat Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52(3):340–52.PubMedCrossRefPubMedCentral Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, Jiang Y, Zhou X, Li TT, Guan KL, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52(3):340–52.PubMedCrossRefPubMedCentral
18.
Zurück zum Zitat Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y et al: PKM2 Regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 2014;53(1):75–87. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y et al: PKM2 Regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 2014;53(1):75–87.
19.
Zurück zum Zitat Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–9.PubMedCrossRef Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64(11):3892–9.PubMedCrossRef
20.
Zurück zum Zitat Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7–8):1358–66.PubMedCrossRef Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7–8):1358–66.PubMedCrossRef
21.
Zurück zum Zitat Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB, Song YS. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2013. doi:10.1007/s10238-013-0250-9. Suh DH, Kim MA, Kim H, Kim MK, Kim HS, Chung HH, Kim YB, Song YS. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med. 2013. doi:10.​1007/​s10238-013-0250-9.
22.
Zurück zum Zitat Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agro A, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797–802.PubMedCrossRef Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D’Alessandro A, Zolla L, Finazzi Agro A, et al. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene. 2013;32(6):797–802.PubMedCrossRef
23.
Zurück zum Zitat Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer. 2012;12:232.PubMedCrossRef Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer. 2012;12:232.PubMedCrossRef
24.
Zurück zum Zitat Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2009;56(90):355–60.PubMed Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H. Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2009;56(90):355–60.PubMed
25.
Zurück zum Zitat Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res MCR. 2009;7(9):1438–45.CrossRef Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res MCR. 2009;7(9):1438–45.CrossRef
26.
Zurück zum Zitat Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP, Liang HJ. Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 2008;54(5):357–63.PubMedCrossRef Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP, Liang HJ. Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 2008;54(5):357–63.PubMedCrossRef
27.
Zurück zum Zitat Gjesing AP, Nielsen AA, Brandslund I, Christensen C, Sandbaek A, Jorgensen T, Witte D, Bonnefond A, Froguel P, Hansen T, et al. Studies of a genetic variant in HK1 in relation to quantitative metabolic traits and to the prevalence of type 2 diabetes. BMC Med Genet. 2011;12:99.PubMedCrossRefPubMedCentral Gjesing AP, Nielsen AA, Brandslund I, Christensen C, Sandbaek A, Jorgensen T, Witte D, Bonnefond A, Froguel P, Hansen T, et al. Studies of a genetic variant in HK1 in relation to quantitative metabolic traits and to the prevalence of type 2 diabetes. BMC Med Genet. 2011;12:99.PubMedCrossRefPubMedCentral
Metadaten
Titel
Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival
verfasst von
Wenfeng Li
Zhengyang Xu
Junfeng Hong
Yunsheng Xu
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 9/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0118-1

Weitere Artikel der Ausgabe 9/2014

Medical Oncology 9/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.